The CONFORM Pivotal Trial

Launched by CONFORMAL MEDICAL, INC · Nov 24, 2021

Keywords

ClinConnect Summary

The CONFORM Pivotal Trial is studying a new device called the CLAAS® that aims to help patients with non-valvular atrial fibrillation (AF) reduce their risk of stroke. In this trial, eligible participants will be randomly assigned to receive either the CLAAS device or one of the existing devices, the WATCHMAN® or Amulet™, which are already available. The goal is to see if the CLAAS device is just as safe and effective as these established options. Participants will be monitored for five years after receiving their device to track their health and any potential complications.

To be eligible for this trial, participants must be at least 18 years old, have a documented history of atrial fibrillation, and be at a higher risk for stroke, as indicated by a specific scoring system. They should also be looking for an alternative to long-term blood-thinning medications. However, certain conditions, such as pregnancy, recent major surgeries, or specific heart problems, may disqualify potential participants. If you decide to join the trial, you’ll receive thorough information about the study and will need to give your written consent. Overall, this trial could provide valuable insights into a new treatment option for those at risk of stroke due to atrial fibrillation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or non-pregnant female aged ≥18 years
• • 2. Documented non-valvular AF (paroxysmal, persistent, or permanent)
• • 3. High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3
• • 4. Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation
• • 5. Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.
• • 6. Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care
• • 7. Able to comply with the protocol-specified medication regimen and follow-up evaluations
• • 8. The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC).
• Exclusion Criteria:
• • 1. Pregnant or nursing patients and those who plan pregnancy in the period up to one year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
• • 2. Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., atrial septal defect (ASD) requiring closure, high-risk patent foramen ovale (PFO) requiring closure, a highly mobile inter-atrial septal aneurysm precluding a safe TSP, presence of a PFO/ASD closure device, history of surgical ASD repair or history of surgical LAAO closure)
• • 3. Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
• • 4. A medical condition (other than atrial fibrillation) that mandates long-term oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or prosthetic mechanical heart valve)
• • 5. History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated
• • 6. Documented active systemic infection
• • 7. Symptomatic carotid artery disease (defined as \>50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is \<50% stenosis noted at the site of prior treatment
• • 8. Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or major non-cardiac interventional or surgical procedure
• • 9. Recent (within 30 days of index procedure) stroke or transient ischemic attack
• • 10. Recent (within 30 days of index procedure) myocardial infarction
• • 11. Vascular access precluding delivery of implant with catheter-based system
• • 12. Severe heart failure (New York Heart Association Class IV)
• • 13. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any prosthetic mechanical valve implant
• • 14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation)
• • 15. Platelet count \<75,000 cells/mm3 or \>700,000 cells/mm3, or white blood cell count \<3,000 cells/mm3
• • 16. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium) that would preclude any P2Y12 inhibitor therapy, or the patient has contrast sensitivity that cannot be adequately pre-medicated
• • 17. Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial
• • 18. Unable to undergo general anesthesia
• • 19. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years
• • 20. A condition which precludes adequate transesophageal echocardiographic assessment
• Echo exclusion criteria:
• • 1. Left atrial appendage anatomy which cannot accommodate a commercially available control device or the CLAAS Implant per manufacturer IFU (e.g., the anatomy and sizing must be appropriate for both the investigational (CLAAS) and a commercially available device in order to be enrolled in the trial)
• • 2. Intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as visualized by TEE prior to implant
• • 3. Left ventricular ejection fraction (LVEF) \<30%
• • 4. Moderate or large circumferential pericardial effusion \>10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology
• • 5. Atrial septal defect that warrants closure
• • 6. High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion \>15 mm or length \> 15 mm) or large shunt (early \[within 3 beats\] and/or substantial passage of bubbles, e.g., \>20)
• • 7. Moderate or severe mitral valve stenosis (mitral valve area \<1.5 cm2)
• • 8. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
• • 9. Evidence of cardiac tumor